

maintenance, and implementation of written mitigation strategies and procedures for defense monitoring, corrective actions, and food defense verification procedures.

To help facilitate the submission to FDA of required information and reduce burden on respondents, we have developed resources, including an “FDA Food Defense Plan Builder,” (version 2.0) available at <https://www.fda.gov/food/food-defense/food-defense-tools-educational-materials>. Other resources made available to respondents include two draft guidance documents entitled “Mitigation Strategies To Protect Food Against

Intentional Adulteration: Draft Guidance for Industry” (84 FR 8103, March 6, 2019), and “Supplemental Draft Guidance for Industry: Mitigation Strategies To Protect Food Against Intentional Adulteration” (85 FR 8599, February 14, 2020), which are available at <https://www.fda.gov/food/food-defense>. The guidance documents are intended to assist respondents in developing and implementing requisite elements of a food defense plan. All Agency guidance documents are issued in accordance with our good guidance practice regulations in 21 CFR 10.115, which provide for public comment at any time. Finally, we developed the

small entity compliance guide entitled “Mitigation Strategies To Protect Food Against Intentional Adulteration” (82 FR 40484, August 25, 2017), available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-mitigation-strategies-protect-food-against-intentional-adulteration>.

Description of Respondents: The respondents to this information collection are manufacturers, processors, packers, and holders of retail food products marketed in the United States.

We estimate the burden of the collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN¹

Information collection activity; 21 CFR section	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Exemption requests for very small businesses; § 121.5	18,080	1	18,080	0.5 (30 minutes)	9,040

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN¹

Activity; 21 CFR section	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per recordkeeping	Total hours
Food Defense Plan; § 121.126	3,247	1	3,247	23	74,681
Actionable Process Steps; § 121.130	9,759	1	9,759	20	195,180
Mitigation Strategies; § 121.135(b)	9,759	1	9,759	20	195,180
Monitoring, Corrective Actions, Verification; §§ 121.140(a), 121.145(a)(1), and 121.150(b).	9,759	1	9,759	175	1,707,825
Training; § 121.4	367,203	1	367,203	0.67 (40 minutes)	246,026
Records; §§ 121.305 and 121.310	9,759	1	9,759	10	97,590
Total					2,516,482

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our burden estimate.

Dated: June 24, 2025.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2025–12308 Filed 7–1–25; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Investigator initiated Program Project Applications.

Date: July 29–30, 2025.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Vanitha Sundaresa Raman, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 301–761–7949, vanitha.raman@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Development of Radiation/Nuclear Medical

Countermeasures (MCMs) And Biodosimetry Devices.

Date: July 31–August 1, 2025.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate contract proposals.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Sandip Bhattacharyya, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, sandip.bhattacharyya@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: AD/ADRD- and Aging-Related Outcomes.

Date: August 5, 2025.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Surojeet Sengupta, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Neurological Disorders and Stroke, 6001 Executive

Boulevard, Room 5134, Bethesda, MD 20892, (301) 496-9223, surojeet.sengupta@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Molecular and Cellular Topics in Basic Neuroscience.

Date: August 5–6, 2025.

Time: 9:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, Bethesda, MD 20892, (301) 827-4471, ramadanir@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Miniaturization and Automation of Tissue Chip Systems (MATCHS).

Date: August 5, 2025.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Bruce Sundstrom, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G11A, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892-9834, (240) 669-5045, sundstromj@niaid.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Career Development and Research Education Programs.

Date: August 5, 2025.

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Chee Lim, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4128, Bethesda, MD 20892, (301) 435-1850, limc4@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Endocrine and Metabolic Systems.

Date: August 6, 2025.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Zhuqing Li, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3G41B, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892-9834, (240) 669-5068, zhuqing.li@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel;

Fellowships: Aging, Neurodegeneration, and Neurotoxicology.

Date: August 6–7, 2025.

Time: 9:30 a.m. to 8:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Rahat Rani Khan, Ph.D., Scientific Review Officer, Office of Grants Management and Scientific Review, National Center for Advancing Translational Sciences, 6701 Democracy Blvd., Rm. 1078, Bethesda, MD 20892, 301-594-7319, Khanr2@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Molecular Genetics and Genomics

Date: August 6–7, 2025.

Time: 9:30 a.m. to 5:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Dharmendar Rathore, Ph.D., Chief, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute on Drug Abuse, NIH 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 402-6965, dharmendar.rathore@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Topics in Infectious Disease.

Date: August 6, 2025.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jennifer Hartt Meyers, Ph.D., Scientific Review Program, DEA/ NIAID/NIH/DHHS, 5601 Fishers Lane, MSC-9823, Rockville, MD 20852, 301-761-6602, jennifer.meyers@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 30, 2025.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025-12378 Filed 7-1-25; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive, Inter-Institutional Agreement-Institution Lead: Generation of Antigen-Specific T and B Cells Using Engineered Commensals

AGENCY: National Institutes of Health, National Institute of Allergy and Infectious Diseases, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Inter-Institutional Agreement-Institution Lead to CZ Biohub SF, LLC (“CZB”), located in San Francisco, California, in its rights to the technologies and patent applications listed in the Supplementary Information section of this notice.

DATES: Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, on or before July 17, 2025 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive, Inter-Institutional Agreement-Institution Lead should be directed to: Jonathan Motley, Ph.D., Technology Transfer and Patent Specialist, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, 6D29, MSC9804, Rockville, MD 20852-9804, phone number 240-669-5209, or jonathan.motley@nih.gov.

SUPPLEMENTARY INFORMATION: The following and all continuing U.S. patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to CZB: United States Provisional Patent Application Serial No. 63/588,398, filed October 6, 2023, the title of which is “Generation Of Antigen-Specific T And B Cells Using Engineered Commensals” (HHS Reference No. E-047-2024-0-US-01); and PCT Application Number PCT/US24/50039, filed October 4, 2024 (HHS Reference No. E-047-2024-0-PC-01), the title of which is “Generation Of Antigen-Specific T And B Cells Using Engineered Commensals”.

The patent rights to this technology have been assigned to CZB, The Board Of Trustees Of The Leland Stanford